CNMV
Markets Directorate General
C/ Edison núm. 4
28006 Madrid

Madrid, 19 December, 2024

In accordance with the provisions of article 227 of the Spanish Securities Markets and Investment Services Act (*Ley de los Mercados de Valores y de los Servicios de Inversión*), approved by Law 6/2023, of 17 March, and concordant provisions, is hereby reported the following:

OTHER RELEVANT INFORMATION

Pharma Mar, S.A. announces that the Phase III LAGOON clinical trial, which evaluates Zepzelca® (lurbinectedin) for the treatment of patients with relapsed Small Cell Lung Cancer (SCLC), has achieved its recruitment target of 705 patients.

Please find attached press release that Pharma Mar, S.A. will distribute to the media.

Pharma Mar S.A.
Avda. de los Reyes, 1
P.I. La Mina
28770 Colmenar Viejo
(Madrid) Spain
www.pharmamar.com

Press Release

PharmaMar completes enrollment for phase III LAGOON study with Zepzelca® (lurbinectedin) for the treatment of small cell lung cancer

- **The LAGOON study has enrolled 705 patients across more than 200 sites around the world.**
- **Top-line data are expected in the first quarter of 2026.**

Madrid, December 19th, 2024.- PharmaMar (MSE: PHM) today announced that the Phase III LAGOON clinical trial, which evaluates Zepzelca® (lurbinectedin) for the treatment of patients with relapsed small cell lung cancer (SCLC), has achieved its recruitment target of 705 patients.

LAGOON is a randomized (1:1:1), multicenter, open-label Phase III clinical trial with three arms: in the first arm, patients receive lurbinectedin as monotherapy; in the second arm, lurbinectedin is administered in combination with irinotecan; and in the third arm, patients are treated with physician's choice of topotecan or irinotecan. The study enrolled patients with SCLC whose disease has progressed after one prior line of platinum-based chemotherapy, with or without anti-PD-1 or anti-PD-L1 agents.

The primary objective of the trial is to evaluate overall survival (OS) and progression-free survival (PFS) is one of the secondary endpoints. Top-line results from the study are anticipated in the first quarter of 2026.

Lurbinectedin received accelerated approval from the FDA in June 2020 for the treatment of adult patients with metastatic SCLC whose disease has progressed during or after platinum-based chemotherapy. Since then, it has been approved in 17 territories, including recently in China, although in Europe it has only received approval in Switzerland.

Lurbinectedin is also being investigated in the Phase 3 IMforte clinical trial in combination with atezolizumab compared to atezolizumab alone when administered as a maintenance treatment for adults with extensive-stage small cell lung cancer (ES-SCLC) following induction therapy with carboplatin, etoposide and atezolizumab. As previously announced in October 2024 by Jazz Pharmaceuticals and PharmaMar, the preliminary results from the IMforte trial demonstrated a statistically significant improvement in the primary endpoints of OS and PFS, as assessed by an independent review facility (IRF), for the combination compared to treatment with atezolizumab alone.

SCLC accounts for 15% of all lung cancer diagnoses and is among the most aggressive cancer types. It is characterized by its rapid growth, invasive nature, and early metastasis. Approximately 70% of cases are diagnosed at advanced stages. While the disease often initially responds well to treatment, it tends to recur frequently. [iii]

Legal warning

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About PharmaMar

PharmaMar is a biopharmaceutical company focused on the research and development of new oncology treatments, whose mission is to improve the healthcare outcomes of patients afflicted by serious diseases with our innovative medicines. The Company is inspired by the sea, driven by science, and motivated by patients with serious diseases to improve their lives by delivering novel medicines to them. PharmaMar intends to continue to be the world leader in marine medicinal discovery, development and innovation.

PharmaMar has developed and now commercializes Yondelis® in Europe by itself, as well as Zepzelca® (lurbinectedin), in the US; and Aplidin® (plitidepsin), in Australia, with different partners. In addition, it has a pipeline of drug candidates and a robust R&D oncology program. PharmaMar has other clinical-stage programs under development for several types of solid cancers: lurbinectedin, ecubectedin, PM534 and PM54.. Headquartered in Madrid (Spain), PharmaMar has subsidiaries in Germany, France, Italy, Belgium, Austria, Switzerland and The United States. PharmaMar also wholly owns Sylentis, a company dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at www.pharmamar.com.

About Zepzelca®

Zepzelca® (lurbinectedin), also known as PM1183, is an analog of the marine compound ET-736 isolated from the sea squirt Ecteinascidia turbinata in which a hydrogen atom has been replaced by a methoxy group. It is a selective inhibitor of the oncogenic transcription programs on which many tumors are particularly dependent. Together with its effect on cancer cells, lurbinectedin inhibits oncogenic transcription in tumor-associated macrophages, downregulating the production of cytokines that are essential for the growth of the tumor. Transcriptional addiction is an acknowledged target in those diseases, many of them lacking other actionable targets.

Media Contact:

Lara Vadillo – Communication Director lvadillo@pharmamar.com

Miriam Collados Gordo – Corporate Communication Manager mcollados@pharmamar.com

Phone: +34 918466000

Capital Markets & Investor Relations:

José Luis Moreno– VP Capital Markets & Investor Relations

Natalia Amo – Capital Markets & Investor Relations

investorrelations@pharmamar.com

Phone: +34 914444500

Or please visit our website at **www.pharmamar.com**

[i] Tratamiento del cáncer de pulmón de células pequeñas (PDQ®). (s. f.). Cancer.gov. https://www.cancer.gov/espanol/tipos/pulmon/pro/tratamiento-pulmon-celulas-pequenas-pdq

ii Facp, W. W. T. M. (s. f.-b). Small cell lung Cancer (SCLC): Practice essentials, pathophysiology, etiology. https://emedicine.medscape.com/article/280104-overview?form=fpf#a1